Head to head!

FinishingLinan

The price of Lilly’s recently approved diabetes drug Mounjaro (tirzepatide) was exposed, with a monthly treatment price of about $974 (4 sticks), which is lower than Novo Nordisk’s weight loss drug Wegovy (semaglutide, GLP-1 receptor body agonist, 4 mg weekly subcutaneously), which is priced at $1,349 per mon.

For Lilly's pricing, Wells Fargo analyst Mohit Bansal said it "may open the door to off-label use" as Mounjaro has demonstrated advantages over Wegovy in late-stage tria.

Data show that Tirzepatide is a first-in-class drug that activates both GLP-1 and GIP receptors, and this activation can improve glycemic contr.

The approval is based on positive results from the Phase III SURPASS program, a large Phase III program consisting of 10 clinical trials planned to enroll more than 13,000 patients with type 2 diabetes, five of which are global registry studi.

Glucagon-like peptide-1 (GLP-1) can be said to be the "all-rounder" hormo.

In recent years, GLP-1 receptor targets are becoming the mainstream of weight loss drug research and developme.

The approval is based on results from the STEP Phase 3a clinical trial program involving more than 4,500 obese or overweight adult patien.

Wegovy's approval as a weight loss therapy has some advantag.

On April 28, 2022, Eli Lilly announced key data from the SURMOUNT-1 study, a 72-week placebo-controlled study of the potential blockbuster GLP1/GIP dual agonist Tirzepatide (a weekly subcutaneous formulatio.

The data showed that the tirzepatide (5mg, 10mg, 15mg) treatment group achieved significantly better weight loss at week 72 than the placebo control group, with an average weight loss of up to 25% (24kg) and 63% in the 15mg high-dose group of patients lost more than 20% of their body weig.

Eli Lilly CEO Dave Ricks has previously said that Lilly is considering, like Novo Nordisk, dividing the tirzepatide brand into diabetes and obesity and marketing them separate.

And Tirzepatide is also expected to become another trump card in the diabetes market after Eli Lilly succeeds dulagluti.

In China, pharmaceutical companies such as Renhui Bio, Huadong Medicine, Wanbang Biochemical, Hengrui Medicine, and Hansen Pharmaceutical are also competing for the GLP-1 receptor agonist product pipeli.

Reference article:

"Top 10 Most Anticipated New Drugs in the Market in 2022" Yiyi Medicine, 2022-02-08

"Pharmaceutical Market Patterns in the Top 10 Hot Sectors in the World in 2021" Medicine Cube, 2022-04-25

"Latest! Eli Lilly's new diabetes drug is priced lower than semaglutide, and wants to seize the weight loss market" Medicine Universe, 2022-05-22

The price of the blockbuster GLP-1 new drug Tirzepatide is here! 》Pharmaceutical Financing, 2022-05-22